Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol

302 patients with implantable cardioverter-defibrillators, stratified by left ventricular ejection fraction (<=0.30 or >0.30).

Sotalol 160 to 320 mg per day

Matching placebo

Three end points were used: the delivery of a first shock for any reason or death from any cause, the first appropriate shock for a ventricular arrhythmia or death from any cause, and the first inappropriate shock for a supraventricular arrhythmia or death from any causecomposite